Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT, USA.
Biomedical and Translational Informatics Institute, Geisinger Health System, Danville, PA, USA.
BMC Med Genomics. 2019 Jan 31;12(Suppl 1):13. doi: 10.1186/s12920-018-0453-8.
At least 90% of human genes are alternatively spliced. Alternative splicing has an important function regulating gene expression and miss-splicing can contribute to risk for human diseases, including Alzheimer's disease (AD).
We developed a splicing decision model as a molecular mechanism to identify functional exon skipping events and genetic variation affecting alternative splicing on a genome-wide scale by integrating genomics, transcriptomics, and neuroimaging data in a systems biology approach. In this study, we analyzed RNA-Seq data of hippocampus brain tissue from Alzheimer's disease (AD; n = 24) and cognitively normal elderly controls (CN; n = 50) and identified three exon skipping events in two genes (RELN and NOS1) as significantly associated with AD (corrected p-value < 0.05 and fold change > 1.5). Next, we identified single-nucleotide polymorphisms (SNPs) affecting exon skipping events using the splicing decision model and then performed an association analysis of SNPs potentially affecting three exon skipping events with a global cortical measure of amyloid-β deposition measured by [F] Florbetapir position emission tomography (PET) scan as an AD-related quantitative phenotype. A whole-brain voxel-based analysis was also performed.
Two exons in RELN and one exon in NOS1 showed significantly lower expression levels in the AD participants compared to CN participants, suggesting that the exons tend to be skipped more in AD. We also showed the loss of the core protein structure due to the skipped exons using the protein 3D structure analysis. The targeted SNP-based association analysis identified one intronic SNP (rs362771) adjacent to the skipped exon 24 in RELN as significantly associated with cortical amyloid-β levels (corrected p-value < 0.05). This SNP is within the splicing regulatory element, i.e., intronic splicing enhancer. The minor allele of rs362771 conferred decreases in cortical amyloid-β levels in the right temporal and bilateral parietal lobes.
Our results suggest that exon skipping events and splicing-affecting SNPs in the human hippocampus may contribute to AD pathogenesis. Integration of multiple omics and neuroimaging data provides insights into possible mechanisms underlying AD pathophysiology through exon skipping and may help identify novel therapeutic targets.
人类基因中至少有 90%是可变剪接的。可变剪接在调节基因表达方面具有重要作用,错配剪接可能导致人类疾病的风险,包括阿尔茨海默病(AD)。
我们开发了一种剪接决策模型,作为一种分子机制,通过整合基因组学、转录组学和神经影像学数据,在系统生物学方法中在全基因组范围内识别功能性外显子跳跃事件和影响可变剪接的遗传变异。在这项研究中,我们分析了来自阿尔茨海默病(AD;n=24)和认知正常的老年对照组(CN;n=50)海马组织的 RNA-Seq 数据,并鉴定了两个基因(RELN 和 NOS1)中的三个外显子跳跃事件与 AD 显著相关(校正后的 p 值<0.05,倍数变化>1.5)。接下来,我们使用剪接决策模型鉴定影响外显子跳跃事件的单核苷酸多态性(SNP),然后对可能影响三个外显子跳跃事件的 SNP 进行关联分析,该 SNP 是通过 [F] Florbetapir 位置发射断层扫描(PET)扫描作为 AD 相关的定量表型来测量的全皮质β淀粉样蛋白沉积。还进行了全脑体素分析。
与 CN 参与者相比,AD 参与者的 RELN 中的两个外显子和 NOS1 中的一个外显子的表达水平明显降低,这表明 AD 中外显子更倾向于被跳过。我们还使用蛋白质 3D 结构分析显示了由于外显子跳跃而导致的核心蛋白结构丢失。基于靶向 SNP 的关联分析鉴定出 RELN 中跳过外显子 24 附近的一个内含子 SNP(rs362771)与皮质β淀粉样蛋白水平显著相关(校正后的 p 值<0.05)。该 SNP 位于剪接调控元件内,即内含子剪接增强子。rs362771 的次要等位基因导致右侧颞叶和双侧顶叶皮质β淀粉样蛋白水平降低。
我们的研究结果表明,人类海马体中的外显子跳跃事件和影响剪接的 SNP 可能导致 AD 的发病机制。整合多个组学和神经影像学数据通过外显子跳跃为 AD 病理生理学的潜在机制提供了见解,并可能有助于确定新的治疗靶点。